The Clinical Evaluation of the Dose of Erythropoietins Trial

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are the most used treatment option.

The purpose of this study is

1. the evaluation of biochemical markers to determine the efficacy of individual prediction of ESAs therapy

2. to determine the benefits and harms of different ESA doses therapeutic strategy for the management of anaemia of end stage kidney disease (ESKD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Giovanni FM Strippoli, MD
• Treatments: Epoetin Alfa; Hematinics

Criteria

Inclusion Criteria:

• Age > = 18,

• End stage kidney disease and anemia

• Treatment with hemodialysis for renal replacement therapy

• no contraindications to erythropoietin stimulating agents (ESAs) or already treated with ESAs

Exclusion Criteria:

• Patients with Hb levels > 10 g/dl without ESAs